細胞再程式化市場－全球產業規模、佔有率、趨勢、機會、預測：按技術、應用、最終用戶、地區和競爭對手分類，2021-2031年

全球細胞再程式化市場預計將從 2025 年的 3.3181 億美元大幅成長至 2031 年的 5.3212 億美元，複合年成長率為 8.19%。

細胞再程式化技術可以將成熟的體細胞轉化為誘導性多功能幹細胞（iPS細胞）或其他細胞類型，從而實現無需依賴胚胎來源細胞即可開發個人化再生醫學治療方法。這項市場擴張的主要驅動力是全球慢性病和退化性疾病發生率的不斷上升，這些疾病需要創新治療方法，以及對轉化研究的持續投入。這些關鍵因素表明，醫療保健產業正在發生根本性的轉變，從依賴暫時的技術進步轉向為個別患者量身定做的生物根治性方案。

然而，儘管成長前景可觀，但市場面臨的主要障礙是生產規模化難度。持續大規模生產臨床級細胞在技術上仍然十分複雜，成本也極為高昂。這種低生產效率成為瓶頸，阻礙了監管核准，限制了患者的廣泛應用。根據再生醫學聯盟預測，到2025年，全球整體再生醫療產業預計將吸引152億美元的投資。這凸顯了克服生產難題和推動臨床開發所需的巨額資金。

市場促進因素

關鍵市場促進因素包括細胞再程式化領域的技術和調查方法進步，特別是非整合遞送載體和體內再程式化技術的開發。這些創新有效解決了與病毒載體相關的安全問題，並簡化了傳統體外方法的複雜操作流程。透過實現患者體內細胞的直接轉化，並提高誘導多功能細胞（iPS細胞）生成的精確度，這些進步使開發人員能夠繞過重大的生產障礙。例如，Capstan Therapeutics於2024年3月獲得超過1.75億美元的B輪資金籌措，用於推進標靶體內工程遞送系統的開發。這凸顯了投資者對前沿重編程方法的堅定信心。

此外，生命科學產業內部的策略聯盟和夥伴關係也是關鍵的驅動力，它們建構了將實驗平台轉化為商業產品所需的必要基礎設施。大型製藥企業正積極收購或與專業的生物技術公司合作，以獲取專有的分化方案和先進的高通量生產能力。例如，Vertex 和 TreeFrog Therapeutics 於 2024 年 4 月簽署了一項許可協議，該協議利用新型細胞生產技術治療第 1 型糖尿病。據估計，該協議的潛在價值為 7.8 億美元。這種整合趨勢凸顯了該市場的商業性潛力。根據美國基因與細胞治療學會的報告，截至 2024 年，全球共有 4073 種基因、細胞和 RNA 療法正在研發中，凸顯了這些合資企業如何拓展臨床應用範圍。

市場挑戰

全球細胞再程式化市場面臨的主要結構性障礙是生產規模化，這嚴重阻礙了從成功的臨床試驗到廣泛商業化的轉化。儘管研究進展迅速，但大規模生產臨床級誘導多功能細胞（iPS細胞）的技術複雜性仍然是重要的生產瓶頸。在大規模生產中保持生物學品質的一致性和控制仍然極其困難，導致營運成本過高，直接削弱了新型治療方法惠及更廣泛患者群體的經濟可行性。

因此，這些生產限制制約了市場的商業性規模，大部分收入集中在少數能夠克服物流障礙的治療方法上。根據再生醫學聯盟的數據，到2025年，該領域全球75%的銷售額預計將來自不到10種市售產品。這種價值集中凸顯了企業在將多元化的臨床研發管線轉化為市場認可的治療方法所面臨的挑戰。在生產效率提高之前，這些複雜生物過程相關的高昂單位成本將繼續阻礙市場擴張，並限制患者獲得創新再生醫學解決方案的機會。

市場趨勢

一個關鍵趨勢是將人工智慧 (AI) 整合到方案最佳化中，這正在透過用預測性計算建模取代傳統的試驗錯法來改變市場。開發人員擴大利用機器學習演算法來模擬細胞行為並改進再程式化組合，從而顯著提高誘導性多功能幹細胞(iPS 細胞) 的產量和可靠性。這種數位轉型不僅縮短了漫長的製程開發週期，而且透過提高生物學一致性，直接降低了通常會阻礙臨床應用的變異性。例如，在 2025 年 3 月舉行的 NVIDIA GTC 2025 大會上，NVIDIA 宣布與 Google Cloud 和 GE Healthcare 建立策略合作夥伴關係，並展示了一個旨在加速生物技術領域運算任務和最佳化自主生命科學應用的 AI 驅動平台。

同時，人們對錶觀遺傳再生和部分重編程的興趣日益濃厚，這標誌著治療理念從單純替換細胞轉向主動恢復細胞功能，尤其針對老化過程。與引入新細胞的傳統治療方法不同，這種方法透過暫時表達重編程因子，在不改變組織固有特性的前提下，重置現有組織內的表觀遺傳時鐘。這種創新方法有望治療與老齡化相關的衰退，並吸引了大量私人投資。這印證了該行業正從治療性療法轉向預防性長壽干預措施。根據《財星》雜誌2025年1月報道，Retro Biosciences公司當時正在進行一輪10億美元的融資，以推進一項旨在逆轉老齡化相關資金籌措機制並延長人類健康壽命的治療方法的臨床試驗。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球細胞再程式化市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依技術分類（仙台病毒技術、mRNA再程式化技術等）
  • 透過應用（監測、治療）
  • 按最終用戶（研究和學術機構、生物技術和製藥公司、醫院和診所、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美細胞再程式化市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲細胞再程式化市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區細胞再程式化市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東與非洲細胞再程式化市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美細胞再程式化市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球細胞再程式化市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Allele Biotechnology co. ltd.
• ALSTEM, INC
• Applied Biological Materials Inc.
• Axol Bioscience Ltd.
• Fujifilm Cellular Dynamics inc.
• Lonza Group AG
• Mogrify inc.
• REPROCELL Inc.
• Stemnovate Limited
• Thermo Fisher Scientific Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The global cell reprogramming market is projected to expand significantly, rising from USD 331.81 million in 2025 to USD 532.12 million by 2031, demonstrating an 8.19% compound annual growth rate. Cell reprogramming involves transforming mature somatic cells into induced pluripotent stem cells (iPSCs) or directly into other cell types, enabling the creation of personalized regenerative treatments without relying on embryonic sources. This market expansion is primarily driven by the increasing worldwide incidence of chronic and degenerative diseases, which demand innovative treatments, alongside consistent investment in translational research. These core factors signify a fundamental shift in healthcare towards personalized, curative biological solutions, rather than temporary technological advancements.

However, despite this promising growth trajectory, a substantial obstacle for the market is the difficulty in scaling manufacturing. Producing clinical-grade cells consistently and in commercial quantities remains technically intricate and excessively costly. This inefficiency in production creates a bottleneck, hindering regulatory approvals and limiting broad patient access. In 2025, the regenerative medicine industry attracted $15.2 billion in global investments, as reported by the Alliance for Regenerative Medicine, highlighting the substantial financial resources needed to overcome manufacturing challenges and advance clinical development.

Market Driver

Key market drivers include technological and methodological advancements in cell reprogramming, particularly the development of non-integrating delivery vectors and in vivo reprogramming techniques. These innovations effectively resolve safety issues linked to viral vectors and simplify the complex operational procedures of conventional ex vivo methods. By facilitating direct cellular transformation within patients or enhancing the precision of induced pluripotent stem cell generation, these advancements allow developers to bypass significant manufacturing obstacles. For instance, Capstan Therapeutics secured over $175 million in Series B financing in March 2024 to advance its targeted in vivo engineering delivery systems, underscoring strong investor belief in cutting-edge reprogramming approaches.

Furthermore, strategic collaborations and partnerships within the life sciences industry serve as another crucial catalyst, establishing the infrastructure needed to translate experimental platforms into commercial products. Major pharmaceutical companies are actively acquiring or collaborating with specialized biotech firms to gain access to unique differentiation protocols and advanced high-throughput manufacturing capabilities. An example is the April 2024 licensing agreement between Vertex and TreeFrog Therapeutics, potentially valued at $780 million, to utilize a novel cell production technology for type 1 diabetes treatments. This consolidation trend affirms the market's commercial potential, supported by 4,073 gene, cell, and RNA therapies globally in development in 2024, as reported by the American Society of Gene & Cell Therapy, highlighting the expanding range of clinical applications driven by these joint ventures.

Market Challenge

The primary structural barrier to the Global Cell Reprogramming Market is manufacturing scalability, which severely impedes the progression from successful clinical trials to broad commercial availability. Despite rapid advancements in research, the technical complexities involved in producing clinical-grade induced pluripotent stem cells (iPSCs) in industrial quantities create a significant production bottleneck. Maintaining consistent biological quality and control during large-scale manufacturing remains exceptionally challenging, leading to prohibitively high operational costs that directly undermine the economic feasibility of new therapies for a wider patient base.

As a result, these manufacturing limitations restrict the market's commercial scope, channeling significant financial returns to a select group of therapies that have managed to overcome these logistical obstacles. Data from the Alliance for Regenerative Medicine indicates that in 2025, a substantial 75% of the sector's global revenue originated from fewer than ten commercially available products. This concentrated value underscores the difficulties companies face in translating diverse clinical pipelines into viable marketable treatments. Until production efficiency improves, the high per-unit costs associated with these intricate biological processes will continue to hinder market expansion and limit patient access to innovative regenerative solutions.

Market Trends

A key trend is the integration of Artificial Intelligence for protocol optimization, which is transforming the market by replacing traditional trial-and-error approaches with predictive computational modeling. Developers are increasingly leveraging machine learning algorithms to simulate cellular behaviors and refine reprogramming cocktails, leading to substantial improvements in the yield and reliability of induced pluripotent stem cells. This digital shift not only shortens the lengthy process development cycle but also ensures greater biological consistency, directly mitigating the variability that often impedes clinical translation. For instance, at NVIDIA GTC 2025 in March 2025, NVIDIA revealed strategic collaborations with Google Cloud and GE HealthCare to implement AI-driven platforms aimed at accelerating biotech computational tasks and optimizing autonomous life sciences applications.

Concurrently, there is a growing focus on epigenetic rejuvenation and partial reprogramming, marking a significant shift from simply replacing cells to actively restoring cellular function, specifically targeting the aging process. Unlike conventional therapies that introduce new cells, this method involves transiently expressing reprogramming factors to reset the epigenetic clock within existing tissues without altering their original identity. This innovative approach holds promise for treating age-related decline and is attracting substantial private investment, affirming the industry's move towards preventative longevity interventions in addition to curative therapies. As reported by Fortune in January 2025, Retro Biosciences was pursuing a $1 billion funding round to advance clinical trials for therapies aimed at reversing age-related disease mechanisms and extending human healthspan.

Key Market Players

• Allele Biotechnology co. ltd.
• ALSTEM, INC
• Applied Biological Materials Inc.
• Axol Bioscience Ltd.
• Fujifilm Cellular Dynamics inc.
• Lonza Group AG
• Mogrify inc.
• REPROCELL Inc.
• Stemnovate Limited
• Thermo Fisher Scientific Inc

Report Scope

In this report, the Global Cell Reprogramming Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Reprogramming Market, By Technology

• Sendai Virus-based
• mRNA Reprogramming
• Others

Cell Reprogramming Market, By Application

• Research
• Therapeutic

Cell Reprogramming Market, By End User

• Research & Academic Institutes
• Biotechnology & Pharmaceutical Companies
• Hospitals & Clinics
• Others

Cell Reprogramming Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Reprogramming Market.

Available Customizations:

Global Cell Reprogramming Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Reprogramming Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Sendai Virus-based, mRNA Reprogramming, Others)
  • 5.2.2. By Application (Research, Therapeutic)
  • 5.2.3. By End User (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cell Reprogramming Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell Reprogramming Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Cell Reprogramming Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Cell Reprogramming Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Cell Reprogramming Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell Reprogramming Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Cell Reprogramming Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Cell Reprogramming Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Cell Reprogramming Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Cell Reprogramming Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Cell Reprogramming Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell Reprogramming Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Cell Reprogramming Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Cell Reprogramming Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Cell Reprogramming Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Cell Reprogramming Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Cell Reprogramming Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell Reprogramming Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Cell Reprogramming Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Cell Reprogramming Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Cell Reprogramming Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell Reprogramming Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Cell Reprogramming Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Cell Reprogramming Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell Reprogramming Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Allele Biotechnology co. ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ALSTEM, INC
• 15.3. Applied Biological Materials Inc.
• 15.4. Axol Bioscience Ltd.
• 15.5. Fujifilm Cellular Dynamics inc.
• 15.6. Lonza Group AG
• 15.7. Mogrify inc.
• 15.8. REPROCELL Inc.
• 15.9. Stemnovate Limited
• 15.10. Thermo Fisher Scientific Inc

16. Strategic Recommendations

17. About Us & Disclaimer